MARKET

XLO

XLO

Xilio Therapeutics, Inc.
NASDAQ
9.05
+0.01
+0.11%
After Hours: 9.05 0 0.00% 16:10 09/28 EDT
OPEN
9.21
PREV CLOSE
9.04
HIGH
9.22
LOW
8.96
VOLUME
11.13K
TURNOVER
--
52 WEEK HIGH
12.74
52 WEEK LOW
6.47
MARKET CAP
59.55M
P/E (TTM)
-5.8766
1D
5D
1M
3M
1Y
5Y
1D
*Xilio Therapeutics Appoints Yariv J. Houvras as Chief Medical Officer
Dow Jones · 12h ago
Press Release: Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
Dow Jones · 12h ago
Weekly Report: what happened at XLO last week (0921-0925)?
Weekly Report · 15h ago
Weekly Report: what happened at XLO last week (0914-0918)?
Weekly Report · 09/21 09:04
Weekly Report: what happened at XLO last week (0907-0911)?
Weekly Report · 09/14 09:04
Weekly Report: what happened at XLO last week (0831-0904)?
Weekly Report · 09/07 09:04
Weekly Report: what happened at XLO last week (0824-0828)?
Weekly Report · 08/31 09:04
Weekly Report: what happened at XLO last week (0817-0821)?
Weekly Report · 08/24 09:04
More
About XLO
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing masked immuno-oncology, or I-O, therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Its pipeline products include Vilastobart, Efarindodekin alfa, XTX501, and masked T cell engagers. Vilastobart is an investigational masked, Fc-enhanced anti-CTLA-4 designed to block CTLA-4 and deplete regulatory T cells when activated (unmasked) in the tumor microenvironment (TME). XTX501 is a novel bispecific PD-1 / masked IL-2 designed to selectively stimulate PD-1 positive, antigen-experienced T cells and enhance their function. Its masked T cell engager programs consist of PSMA and STEAP1 with co-stimulation and CLDN18.2. The masked T cell engagers include molecules with one or more tumor-associated antigen (TAA) binding domains and a CD3 targeting domain.

Webull offers Xilio Therapeutics Inc stock information, including NASDAQ: XLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XLO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XLO stock methods without spending real money on the virtual paper trading platform.